Cadence Pharmaceuticals (CADX -15.8%) takes a hit after announcing plans for a $75M secondary...


Cadence Pharmaceuticals (CADX -15.8%) takes a hit after announcing plans for a $75M secondary stock offering. The company plans to use the majority of the funds for research and development of its injectable acetaminophen drug Ofirmev.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs